Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: polyarticular JIA

FDA Approves Tofacitinib for Young Patients with Active Polyarticular JIA

Michele B. Kaufman, PharmD, BCGP  |  October 9, 2020

Tofacitinib is now FDA approved to treat patients 2 years and older with active, polyarticular juvenile idiopathic arthritis.

Filed under:Drug Updates Tagged with:FDApolyarticular juvenile idiopathic arthritis (JIA)TofacitinibU.S. Food and Drug Administration (FDA)

FDA Approves 2 Upadacitinib Formulations for Children with pJIA & PsA

Michele B. Kaufman, PharmD, BCGP  |  August 13, 2024

Upadacitinib, as a tablet and oral solution, is now FDA approved to treat children age 2 years and older with active polyarticular juvenile idiopathic arthritis or psoriatic arthritis.

Filed under:Biologics/DMARDsConditionsDrug UpdatesPediatric Conditions Tagged with:FDAFDA approvalpJIApolyarticular juvenile idiopathic arthritis (JIA)PsAPsA Resource CenterPsoriatic ArthritisU.S. Food and Drug Administration (FDA)upadacitinib

FDA Approves Sarilumab for pJIA

Michele B. Kaufman, PharmD, BCGP  |  July 29, 2024

The FDA has granted sarilumab its first pediatric indication, approving the agent to treat active, polyarticular juvenile idiopathic arthritis (pJIA) in patients who weigh at least 63 kgs.

Filed under:Biologics/DMARDsConditionsDrug UpdatesPediatric Conditions Tagged with:FDA approvalpJIApolyarticular juvenile idiopathic arthritis (JIA)sarilumabU.S. Food and Drug Administration (FDA)

3 AC&R Study Summaries: Fractures in Patients with SSc, Clinical Response in JIA, & TV & the Public Perception of Gout

Arthritis Care & Research  |  August 13, 2023

Fractures in Patients with SSc By Zsuzsanna McMahan, MD, MHS Why was this study done? To minimize disability due to systemic sclerosis (SSc), it’s important to prevent and manage complications. Many SSc complications and related medications may increase the risk for osteoporosis and fracture. We sought to identify modifiable risk factors for fracture in patients…

Filed under:ConditionsGout and Crystalline ArthritisPatient PerspectivePractice ManagementResearch ReviewsResearch RheumSystemic Sclerosis Tagged with:juvenile idiopathic arthritis (JIA)polyarticular juvenile idiopathic arthritis (JIA)Reading Rheumsystemic sclerosis (SSc)

3 AC&R Study Summaries: Treat to Target in Gout, Response to Biologics in Patients with JIA, & Rehabilitation Dose in Adults with RA

Arthritis Care & Research  |  February 14, 2023

Treat to Target in Gout Monitoring & achievement of target serum urate levels By Jing Li & Gabriela Schmajuk, MD, MS Why was this study done? The ACR’s 2020 guideline for the management of gout recommends using a treat-to-target (T2T) approach to lower serum urate (SU). Using the ACR’s RISE registry, we examined the use…

Filed under:ConditionsGout and Crystalline ArthritisPediatric ConditionsResearch RheumRheumatoid Arthritis Tagged with:GoutGout Resource Centerjuvenile idiopathic arthritis (JIA)

Changing Treatment Patterns for Patients with JIA

Lara C. Pullen, PhD  |  October 18, 2022

A study from Glerup et al. demonstrated that many patients with juvenile idiopathic arthritis achieved drug-free remission over 18 years of follow-up and that remission rates remained stable between years 8 and 18 of the study period.

Filed under:ConditionsPediatric ConditionsResearch RheumRheumatoid Arthritis Tagged with:ChildrenILARJIAjuvenile idiopathic arthritis (JIA)Pediatric

Case Report: Intermittent Fevers in a Patient with pJIA

Osman Bhatty, MD, Dale Kobrin, MD, Lauren Mathos, DO, Nazia Khatoon, MD, Yazan Samhouri, MD, Naga Sai Krishna Patibandla, MD, & Mary Chester Wasko, MD, MSc  |  April 15, 2022

A 26-year-old woman presented to our emergency department (ED) with intermittent fevers, nausea and vomiting. She had a past medical history of well-controlled, anti-nuclear antibody positive and rheumatoid factor negative polyarticular juvenile idiopathic arthritis (pJIA) and Crohn’s disease. Her maintenance treatment consisted of monthly intravenous infliximab, 10 mg of oral methotrexate weekly and 20 mg…

Filed under:ConditionsRheumatoid Arthritis Tagged with:case reportFellowsFellows Forumpolyarticular juvenile idiopathic arthritis (JIA)

A Possible Diagnostic Tool: RheumMadness 2022 AI: JIA Subtypes Scouting Report

The Children’s Hospital at Montefiore Pediatric Rheumatology Fellowship Program: Alisha Akinsete, MD; Malki Peskin, MD; & Jessica Perfetto, MD  |  February 14, 2022

Machine learning is a tool that may help pediatric rheumatologists distinguish between different subtypes of juvenile idiopathic arthritis (JIA) and predict treatment response.

Filed under:ConditionsResearch Rheum Tagged with:AIartificial intelligenceenthesitis-related arthritisJIAjuvenile idiopathic arthritis (JIA)RheumMadnessTechnology

Research on SLE, pJIA & More Highlighted in 2nd ACR Convergence 2021 Plenary Session

Samantha C. Shapiro, MD  |  December 9, 2021

Experts shined a spotlight on select abstracts of the latest rheumatology research, addressing such topics as racial disparities in the management of children with SLE, vitamin D or fish oil supplementation to prevent autoimmune disease & more.

Filed under:ACR ConvergenceConditionsMeeting ReportsPediatric ConditionsSystemic Lupus Erythematosus Tagged with:ACR Convergence 2021ACR Convergence 2021 – SLECOVID-19MIS-CPediatricpJIApolyarticular juvenile idiopathic arthritis

Tofacitinib Yields Rapid & Sustained Improvement in JIA

Reuters Staff  |  December 3, 2021

NEW YORK (Reuters Health)—Tofacitinib significantly reduces the number of flares in children with polyarticular course juvenile idiopathic arthritis (JIA), according to the first phase-3 clinical trial to assess the efficacy of a Janus kinase (JAK) inhibitor in JIA. JIA is a heterogeneous group of chronic conditions with no known cause that develop before age 16…

Filed under:ConditionsRheumatoid Arthritis Tagged with:flareJIAjuvenile idiopathic arthritis (JIA)Tofacitinib

  • 1
  • 2
  • 3
  • …
  • 7
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences